INCAGN01949 + nivolumab + ipilimumab

INCAGN01949 + nivolumab + ipilimumab is an investigational combination therapy composed of three immune checkpoint inhibitors: INCAGN01949 (an anti-OX40 monoclonal antibody), nivolumab (a PD-1 inhibitor), and ipilimumab (a CTLA-4 inhibitor). This regimen is under clinical evaluation for the treatment of advanced malignancies, aiming to enhance antitumor immune responses by simultaneously blocking multiple inhibitory checkpoints and activating T-cell effector functions. Nivolumab and ipilimumab are approved immunotherapies for various cancers, while INCAGN01949 is being developed by Incyte for its immunostimulatory activity via OX40 agonism. The combination leverages complementary mechanisms to potentially improve clinical outcomes versus monotherapies.